BARDA is responsible for developing and procuring technologies and countermeasures to protect the nation against natural and man-made threats. We have delivered solutions to protect our country and the world from threats like Anthrax, Smallpox, Ebola, Pandemic Influenza, and many others. Since it was established in 2006, as part of the Pandemic and All Hazards Preparedness Act, BARDA has facilitated 42 FDA approvals, licensures, and clearances for products addressing a wide range of chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases. BARDA’s mission is accomplished through successful public-private partnerships with industry to share risk, improve efficiency, and accelerate development all while sustaining a marketplace that guarantees continued access to the vaccines, therapeutics, diagnostics, and other medical products that are vital to our national health security.
DRIVe (Division of Research, Innovation, and Ventures) is forming unique public private partnerships. DRIVe will leverage new authorities given to BARDA under the 21st Century Cures Act to stimulate innovation through both non-dilutive funding and dilutive funding. In addition, through our DRIVe Accelerator Network, we will have teams forward deployed throughout the USA to identify promising solutions wherever innovation is happening. Together we are building out an ecosystem of restless innovation, driven by industry and the entrepreneurial community, to address our nation’s largest health security threats.
Too often, people do not receive adequate and timely treatment for infectious diseases like influenza. We either do not seek care, or do so many days late, leading to severe illness, and transmission of infectious agents within the household, at the workplace.
Early Notification to Act, Control, and Treat (ENACT) will disrupt the traditional clinical care paradigm of healthcare being provided outside of the home (within a physician’s office, urgent care center, or hospital). The ENACT program will rapidly leverage the power of transformational technologies to empower individuals to be aware of their own health status and to take action. ENACT leverages advanced data analytics and algorithms coupled with innovative detection modalities to accurately and quickly diagnose patients who have been exposed to pathogens and prognosticate outcomes. ENACT will close the gap between diagnosis and treatment by utilizing the power of telemedicine to bring clinical care into the home. The de-identified data from these individual signals will create real-time information for public health officials about outbreaks in communities.
DRIVe aims to empower people; to give them a greater role in their health outcomes. We will develop biological, biometric, behavioral, and physiological technologies and approaches to identify threats and challenges and put in place systems to mitigate the harm. Better ways to detect threats, point-of-use indicators, biological and physiological sensing technologies – these are the types of solutions that can mean the difference between life and death.
Sepsis is one of the country’s most urgent systemic health threats. Each year, more than 1.5 million people in the U.S. get sepsis. Sepsis kills a quarter-million Americans each year. Sepsis can occur when a trauma or an infection – often caused by a superbug or drug-resistant bacteria in the skin, lungs or urinary tract – triggers a chain reaction throughout the body. This is a cause for daily concern, but would be even more alarming in the aftermath of a Chemical, Biological, Radiological, or Nuclear (CBRN) event – those who survive the initial assault are at high risk of developing sepsis. Without timely recognition and treatment, it can rapidly cause tissue damage, organ failure, and death. One in three patients who die in a hospital have sepsis.
Infections in the lungs (pneumonia), kidney (urinary tract infection), skin, and gut are often associated with sepsis. Bacteria that cause infections that develop into sepsis include Staphylococcus aureus (staph), Escherichia coli (E. coli), and some types of Streptococcus.
Anyone can get sepsis.
What are we doing about it?
DRIVe is seeking bold solutions. These include innovations focused on: